KRAS G12C Inhibition with Sotorasib in Advanced Solid Tumors
David S. Hong, Marwan Fakih, John H. Strickler et al. · New England Journal of Medicine · 2020
BACKGROUND: . METHODS: p.G12C mutation. Patients received sotorasib orally once daily. The primary end point was safety. Key secondary end points were pharmacokinetics and objective response, as assessed according to Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1. RESULTS: A total of 129 patients (59 with NSCLC, 42 with colorectal cancer, and 28 with other tumors) were included in dose escalation and expansion cohorts. Patients had received a median of 3 (range, 0 to 11) previous lines of anticancer therapies for metastatic disease. No dose-limiting toxic effects or treatment-related deaths were observed. A total of 73 patients (56.6%) had treatment-related adverse events; 15 patients (11.6%) had grade 3 or 4 events. In the subgroup with NSCLC, 32.2% (19 patients) had a confirmed objective response (complete or partial response) and 88.1% (52 patients) had disease control (objective response or stable disease); the median progression-free survival was 6.3 months (range, 0.0+ to 14.9 [with + indicating that the value includes patient data that were censored at data cutoff]). In the subgroup with colorectal cancer, 7.1% (3 patients) had a confirmed response, and 73.8% (31 patients) had disease control; the median progression-free survival was 4.0 months (range, 0.0+ to 11.1+). Responses were also observed in patients with pancreatic, endometrial, and appendiceal cancers and melanoma. CONCLUSIONS: p.G12C mutation. Grade 3 or 4 treatment-related toxic effects occurred in 11.6% of the patients. (Funded by Amgen and others; CodeBreaK100 ClinicalTrials.gov number, NCT03600883.).
Cited by 1,715 works. doi:10.1056/nejmoa1917239
Authors
- David S. Hong
- Marwan Fakih
- John H. Strickler
- Jayesh Desai
- Greg Andrew Durm
- Geoffrey Ira Shapiro
- Gerald Steven Falchook
- Timothy Jay Price
- Adrian Gerold Sacher
- Crystal Shereen Denlinger
- Yung‐Jue Bang
- Grace Kho Dy
- John C. Krauss
- Yasutoshi Kuboki
- James Chun-Yen Kuo
- Andrew L. Coveler
- Keunchil Park
- Tae Won Kim
- Fabrice Barlési
- Pamela N. Münster
References
- PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
- Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
- THE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
- COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer
- KRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer
- Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
- K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
- Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer